Long Term Outcome and Prognostic Factors for Large Hepatocellular Carcinoma (10 Cm or More) After Surgical Resection
Overview
Affiliations
Background: Surgical resection is the standard treatment for hepatocellular carcinoma (HCC). However, the role of surgery in treatment of large tumors (10 cm or more) is controversial. We have analyzed, in a single centre, the long-term outcome associated with surgical resection in patients with such large tumors.
Methods: We retrospectively investigated 166 patients who had undergone surgical resection between July 1995 and December 2006 because of large (10 cm or more) HCC. Survival analysis was done using the Kaplan-Meier method. Prognostic factors were evaluated using univariate and multivariate analyses.
Results: Of the 166 patients evaluated, 80% were associated with viral hepatitis and 48.2% had cirrhosis. The majority of patients underwent a major hepatectomy (48.2% had four or more segments resected and 9% had additional organ resection). The postoperative mortality was 3%. The median survival in our study was 20 months, with an actuarial 5-year and 10-year overall survival of 28.6% and 25.6%, respectively. Of these patients, 60% had additional treatment in the form of transarterial chemoembolization, radiofrequency ablation or both. On multivariate analysis, vascular invasion (P < 0.001), cirrhosis (P = 0.028), and satellite lesions/multicentricity (P = 0.006) were significant prognostic factors influencing survival. The patients who had none of these three risk factors had 5-year and 10-year overall survivals of 57.7% each, compared with 22.5% and 19.3%, respectively, for those with at least one risk factor (P < 0.001).
Conclusions: Surgical resection for those with large HCC can be safely performed with a reasonable long-term survival. For tumors with poor prognostic factors, there is a pressing need for effective adjuvant therapy.
TACE vs. TARE for HCC ≥ 8 cm: A propensity score analysis.
Phan N, Chun H, Oh J, Kim S, Choi B Abdom Radiol (NY). 2024; 50(3):1198-1208.
PMID: 39320494 DOI: 10.1007/s00261-024-04573-5.
Li L, Liu C, Li H, Yang J, Pu M, Zhang S J Gastrointest Oncol. 2024; 15(4):1657-1673.
PMID: 39279946 PMC: 11399871. DOI: 10.21037/jgo-24-285.
Garancini M, Serenari M, Famularo S, Cipriani F, Ardito F, Russolillo N Langenbecks Arch Surg. 2024; 409(1):248.
PMID: 39127855 DOI: 10.1007/s00423-024-03419-4.
Patkar S, Shetty O, Vyas K, Vengurlekar V, Kamble V, Shetty N J Clin Exp Hepatol. 2024; 14(6):101445.
PMID: 38975607 PMC: 11222936. DOI: 10.1016/j.jceh.2024.101445.
Gu K, Min J, Lee J, Shin J, Jeong W, Kim Y Eur Radiol. 2024; 34(11):7002-7012.
PMID: 38767659 DOI: 10.1007/s00330-024-10780-x.